Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma

Abstract Background B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T-cell therapy is an emerging treatment option for multiple myeloma. The aim of this systematic review and meta-analysis was to determine its safety and clinical activity and to identify factors influencing...

Full description

Bibliographic Details
Main Authors: Gils Roex, Marijke Timmers, Kristien Wouters, Diana Campillo-Davo, Donovan Flumens, Wilfried Schroyens, Yiwei Chu, Zwi N. Berneman, Eva Lion, Feifei Luo, Sébastien Anguille
Format: Article
Language:English
Published: BMC 2020-12-01
Series:Journal of Hematology & Oncology
Subjects:
BCMA
CAR-T
Multiple myeloma
Online Access:https://doi.org/10.1186/s13045-020-01001-1

Internet

https://doi.org/10.1186/s13045-020-01001-1

Similar Items